Seoul, South Korea
NCT Number: NCT02043145
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines in clinical practice.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines.
Exclusion criteria
- None.
Treatment and study plan
Botulinum toxin type A
BiologicalBotulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
Primary outcomes
-
Number of Patients With Adverse Events (AEs) and Serious Adverse Drug Reactions (SADRs)
Time frame: 4 Years
An AE was defined as any undesirable changes in medical findings (including laboratory test findings) identified during medical examinations as well as AEs associated with the study drug application that occurred during or after administration of the study drug, regardless of causal relationship to the study drug. A SADR was any drug reaction that: resulted in death or was life threatening, required hospitalization or prolonged hospitalization, caused persistent or significant disability/incapacity, caused a congenital anomaly/birth defect or other medically important event.
-
Change From Baseline in the Hyperhidrosis Disease Severity Scale (HDSS) Using a 4-Point Scale
Time frame: Pre-dose (Baseline), Post-dose (Up to 4 Years)
Participants assessed their underarm sweat using the 4-point HDSS where: 1=Never noticeable and never interferes with my daily activities, 2=Tolerable but sometimes interferes with my daily activities, 3=Barely tolerable and frequently interferes with my daily activities or 4=Intolerable and always interferes with my daily activities. A negative change from Baseline indicated improvement.
-
Change From Baseline in the Modified Ashworth Scale (MAS) Using a 6-Point Scale
Time frame: Pre-dose (Baseline), Post-dose (Up to 4 Years)
The MAS assessed the degree of muscle tone during movement of the upper limbs compared to normal muscle tone using a 6-point scale at where: 0=no increase in muscle tone, 1=Slight increase in muscle tone manifested by a catch and release or by minimal resistance at the end of the range of motion when the part is moved, 1+=Slight increase in muscle tone manifested by a catch followed by minimal resistance throughout the remainder of the range of motion, 2=Marked increase in muscle tone through most of the range of motion but affected part easily moved, 3=Considerable increase in muscle tone passive movement difficult or 4=Affected part rigid in movement or extension. A low score indicated little or no stiffness (best). A high score indicated severe stiffness (worse). A negative change from Baseline indicated improvement.
-
Change From Baseline in the Investigator Assessment of Glabellar Line Severity Using a 4-point Scale
Time frame: Pre-dose (Baseline), Post-dose (Up to 4 Years)
The Investigator assessed the severity of the patient's glabellar lines at maximum frown using the 4-point Facial Wrinkle Scale (FWS) where: 0=none, 1=mild, 2=moderate or 3=severe. A negative change from Baseline indicated improvement.
Sponsors and collaborators
Lead sponsor
Allergan
Industry
Registry information
Important dates
- Study start
- 2008
- Primary completion
- 2012
- Study completion
- 2012
- First posted
- Jan 23, 2014
- Registry last updated
- Jun 13, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
NCT04924036
Amputation, Hyperhidrosis
Murray, Utah, United States
View Trial DetailsTreatment of Hyperhidrosis With Oxybutynin
NCT01855256
Hyperhidrosis, Skin Diseases
Morlaix, France
View Trial DetailsComparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
NCT02129660
Hyperhidrosis, Skin Diseases
Encinitas, California, United States
View Trial DetailsA Non-Interventional Study To Assess Sweating
NCT02552199
Hyperhidrosis, Skin Diseases
Carpinteria, California, United States
View Trial Details